Veradigm | MDRX - Selling And Administration Expenses


Veradigm reported $27.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2022.





Selling And Administration Expenses Change Date
Alcidion AUD 1.09M 184K Dec/2025
Ambu A/S DKK 630M 37M Sep/2026
Cardinal Health USD 1.6B 30M Sep/2026
Centene USD 3.24B 132M Sep/2026
Charles River Laboratories USD 140.59M 88.31M Sep/2026
Cigna USD 3.61B 142M Sep/2026
Coloplast 2.64B 52M Dec/2025
Convatec Group USD 420.3M 210.35M Dec/2024
Diasorin EUR 91.47M 35.47M Jun/2026
Elevance Health USD 10.91B 309M Dec/2025
General Electric Aerospace USD 1.09B 40M Sep/2026
Gulf Medical Proj AED 806K 109K Mar/2026
Humana USD 3.36B 614M Mar/2025
IQVIA Holdings USD 569M 5M Sep/2026
Laboratory Of America USD 611.4M 34.2M Sep/2026
Max Healthcare Institute Limited 5.64B 407M Sep/2026
Maximus USD 167.19M 6.29M Jun/2026
McKesson USD 2.27B 5M Sep/2026
Med Life RON 26.47M 3.41M Mar/2026
Molina Healthcare USD 1.21B 19M Sep/2026
Omnicell USD 100.54M 354K Sep/2026
Oriola-kd EUR 13M 3.1M Sep/2025
Owens Minor USD 258.98M 7.5M Dec/2025
Quest Diagnostics USD 523M 6M Sep/2026
Rede D'or Sao Luiz BRL 765.86M 738.14M Sep/2026
Siemens Healthineers EUR 1.08B 68M Sep/2026
Sonova Holding CHF 880.2M 300K Jun/2025
UnitedHealth USD 15.22B 1.44B Sep/2025
Veeva Systems USD 138.88M 12.4M Jun/2026
Veradigm USD 27.28M 5.24M Dec/2022
Xerox USD 368M 10M Jun/2025